Celebrex (celecoxib) : Pharmacia : COX-2 inhibitor

Q&A: NIH Halts Use of COX-2 Inhibitor in Large Cancer Prevention Trial (National Institutes of Health)
Answers to questions regarding the use of celecoxib (Celebrex), a COX-2 inhibitor, in NIH studies, including those investigating celecoxib for the prevention and treatment of lung cancer. Recent reports that COX-2 inhibitors increase the risk of major fatal and non-fatal cardiovascular events have prompted a re-evaluation of ongoing studies. [12/04]

COX-2 Inhibition in NSCLC: Preliminary Results of a Phase II Trial (ASCO)
Abstract of a Phase II study reported at the 2003 ASCO annual meeting to determine the effect of docetaxel plus celecoxib on clinical outcome in patients with advanced NSCLC. Preliminary data indicate that celecoxib inhibits intratumoral COX-2 resulting in decreased tumor PGE2 levels that in turn may modulate downstream angiogenic effects. [6/03]

Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the Response to Preoperative Paclitaxel and Carboplatin in Early Stage NSCLC (ASCO 2002)
Summarizes the findings of a small study that assessed the role of the COX-2 inhibitor celecoxib as an adjunct to preoperative chemotherapy in patients with resectable NSCLC. Data suggest that COX-2 inhibition may significantly enhance the response to preoperative chemotherapy. Confirmatory trials are planned. [2002]

The Role of COX-2 Inhibitors in Lung Cancer (Cancer Innovations)
Good introductory discussion by David Johnson, MD, and Nasser Altorki, MD, two leading researchers in the area of COX-2 inhibition and lung cancer. Includes discussion of Celebrex (celecoxib). [9/02]

Celebrex (celecoxib) - Recent MEDLINE Abstracts

Celebrex (celecoxib) Clinical Trials (ClinicalTrials.gov)